Trial Profile
A phase-II study of stereotactic body radiotherapy and sunitinib for patients with new metastatic renal cell carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Jul 2023
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 06 Jun 2023 Primary endpoint has been met (objective response rate) , according to results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2023 According to results presented at the 59th Annual Meeting of the American Society of Clinical Oncology, complete results are awaited in 2023 after follow-up completion of the entire cohort.
- 06 Jun 2023 Status changed to active, no longer recruiting, according to results presented at the 59th Annual Meeting of the American Society of Clinical Oncology